(Total Views: 340)
Posted On: 12/29/2020 1:23:47 PM
Post# of 63
$4 price target by BTIG's 5 star analyst, Robert Hazlett, helps, but it is old news.
What is more important are the reasons given by Hazlett for his $4 price target:
1. Ongoing LNC trials funded by the NIH and CF Foundation;
2. Soon to be announced results from a second head to head trial of MAT 9001 vs. Vascepa, with results expected to strongly favor MAT 9001; and
3. Collaborations with 5 big pharmaceutical companies, any one of which could choose to purchase MTNB at a huge premium for what would be a pittance for any of these companies.
What is more important are the reasons given by Hazlett for his $4 price target:
1. Ongoing LNC trials funded by the NIH and CF Foundation;
2. Soon to be announced results from a second head to head trial of MAT 9001 vs. Vascepa, with results expected to strongly favor MAT 9001; and
3. Collaborations with 5 big pharmaceutical companies, any one of which could choose to purchase MTNB at a huge premium for what would be a pittance for any of these companies.
(1)
(0)
The Lawman
style="color:red">The Lawman"color:red">The Lawman:red">The LawmanThe Lawmanspan>Lawmanawmanimg]
